Abcellera Biologics Inc Capital Reinvestment Ratio
Abcellera Biologics Inc capital reinvestment ratio. Abcellera Biologics Inc (ABCL) has a Capital Reinvestment Ratio of 1.38x as of June 2023, meaning it reinvests 1% of its operating cash flow ($19.82 Million) in capital expenditures ($27.35 Million). See Abcellera Biologics Inc (ABCL) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Abcellera Biologics Inc (2018–2022)
Capital reinvestment ratio of Abcellera Biologics Inc from 2018 to 2022. This chart tracks Abcellera Biologics Inc's Capital Reinvestment Ratio across 5 annual periods. See Abcellera Biologics Inc financial flexibility index to measure the company's free cash flow as a share of total liabilities.
Abcellera Biologics Inc Capital Reinvestment Ratio by Year (2018–2022)
Abcellera Biologics Inc capital reinvestment ratio by year from 2018 to 2022. For the full cash flow conversion analysis, see Abcellera Biologics Inc operating cash flow efficiency.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2022 | 0.26x | $277.36 Million | $72.66 Million | ▲ +9.6% |
| 2021 | 0.24x | $244.58 Million | $58.45 Million | ▼ -63.0% |
| 2020 | 0.65x | $22.69 Million | $14.67 Million | ▼ -56.4% |
| 2019 | 1.48x | $2.69 Million | $4.00 Million | ▼ -0.3% |
| 2018 | 1.49x | $3.56 Million | $5.31 Million | — |